Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...
STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Promising new research shows Alterity’s novel brain imaging tool could play a key role in diagnosing and tracking Multiple System Atrophy. Quality peer-reviewed publication highlights use of ...
In the future there might be more time for students to study for finals. On Tuesday, the Minnesota Student Association passed a resolution to lobby the University administration and the Board of ...
Shares of Alterity Therapeutics (NASDAQ:ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 ...
The goal is to develop a disease modifying treatment that stops or slow down the progression of alpha-synucleinopathies e.g. Parkinson's disease and MSA. BioArctic's phase 2a study EXIST with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback